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   High levels of psychological distress can influence long-term outcomes for people 
with psoriasis via psychophysiological and behavioural pathways such as alcohol use 
or non-adherence to medication. Beliefs about illness affect how people cope and 
adjust to psoriasis but few studies have explored these relationships in those using 
biologic therapies. We assessed levels of general and psoriasis-specific psychological 
distress and levels of anger experience in patients using conventional systemic and 
biologic therapies. We evaluated factors associated with distress using regression 
analyses.  
   Cross-sectional data from 811 patients using conventional systemic and biologic 
therapies for the treatment of moderate to severe psoriasis and enrolled in the British 
Association of Dermatologists Biologic Interventions Register (BADBIR) were 
collected from 35 dermatology centres across England. We measured anger 
expression (State-Trait Anger Expression Inventory), distress (Hospital Anxiety and 
Depression Scale; HADS), beliefs about psoriasis (Revised Illness Perception 
Questionnaire) and medication (Beliefs about Medicines Questionnaire). A score ≥ 8 
on the HADS indicates a possible or probable caseness of anxiety and/or depression. 
    High proportions of the sample were classified as possible or probable caseness for 
anxiety (40%) and/or depression (24%), with two-thirds reporting strong negative 
psoriasis-specific distress and almost half (47%) reporting strong feelings of anger 
towards their psoriasis. In total, 11.5% reported a high level of anger suppression. 
Stronger suppression of anger was associated with anxiety (standardised beta (β) .401, 
p≤ .001), depression (β .398, p≤ .001) and negative psoriasis-specific distress (β .105, 
p= .001). Holding strong beliefs that psoriasis has negative consequences was 
associated with negative psoriasis-specific distress (β .491, p≤ .001). There were 
different drivers of anxiety and depression with worries about appearance associated 
with anxiety (β .133, p= .006) whereas concerns that psoriasis is noticeable to others 
associated with depression (β .172, p≤ .001). Patients who expressed the strongest 
medication concerns were more likely to report higher depression scores (β .103, p= 
.002). 
   Psychological distress remains high for many patients using systemic therapies. 
Some patients using biologics may require additional interventions to target long-held 
beliefs and address emotion-focused coping strategies in order to improve clinical 
outcomes and quality of life. 
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